Combinatorial chemoprevention of intestinal neoplasia
Combinatorial chemoprevention of intestinal neoplasia
复制标题
DOI：
10.1038/79534
复制
发表时间：
2000-09-01
期刊：
影响因子：
82.9
通讯作者：
Discafani, CM
中科院分区：
文献类型：
--
作者：
Torrance, CJ;Jackson, PE;Discafani, CM
两种药物联合使用对人类家族性腺瘤性息肉病（FAP）小鼠模型APC（Min/+）小鼠的肠道肿瘤形成具有显著的保护作用。其中一种药物是舒林酸，一种典型的非甾体抗炎药，具有确定的化学预防活性。第二种药物是EKI-569，一种新开发的不可逆表皮生长因子受体激酶抑制剂。尽管100%未治疗的APC（Min/+）小鼠出现了-20个息肉，但接受这两种药物治疗的小鼠中有近一半根本没有出现息肉。这些结果为人类结肠肿瘤的化学预防提供了强有力的策略。
A combination of two drugs afforded remarkable protection from intestinal neoplasia in APC(Min/+) mice, a murine model of human familial adenomatous polyposis (FAP). One of the drugs was sulindac, a prototypical non-steroidal anti-inflammatory drug with established chemopreventative activity. The second drug was EKI-569, a newly developed, irreversible inhibitor of the epidermal growth factor receptor kinase. Although 100% of the untreated APC(Min/+) mice developed -20 polyps, nearly half the mice treated with these two agents developed no polyps at all. These results suggest a powerful strategy for the chemoprevention of human colonic neoplasia.